In NAFLD patients, liver PPARα gene expression negatively correlates with NASH severity, visceral adiposity and insulin resistance.46 The serum lipid lowering fibrates are established weak agonists of PPARα used to treat atherogenic dyslipidaemia. This evidence concerns the gene PPARA and Insulin resistance.